Paul Boutros, PhD, MBA, discusses the reasons why some patients with prostate cancer have more aggressive disease than others.
Paul Boutros, PhD, MBA, director of the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center’s Cancer Data Science program and associate director of cancer informatics at the UCLA Institute for Precision Health, discusses the reasons why some patients with prostate cancer have more aggressive disease than others.
Boutros says that aggressive prostate cancer is driven by 5 key processes. The first is genomic instability because tumors that have more mutations are more likely to be deadly. The second process is tumor hypoxia, or the level of oxygen in the tumor. He explains that if there is less oxygen in a tumor, it is more aggressive, and if there is more oxygen and the tumor is more like a normal tissue, the disease will be less aggressive. The third indicator is the presence of an aggressive sub histology called intraductal carcinoma cribriform architecture.
The fourth is whether or not the tumor is visible under a multiparametric MRI, according to Boutros. The last process is the tumors evolution—how clonal, complex, and how branched the tumors evolutionary history is. If you combine these 5 processes, Boutros says that it creates an accurate prediction of which cancers will be more aggressive.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More